Your browser is no longer supported. Please, upgrade your browser.
ALEC [NASD]
Alector, Inc.
Index- P/E- EPS (ttm)-2.44 Insider Own0.30% Shs Outstand79.01M Perf Week-16.15%
Market Cap1.29B Forward P/E- EPS next Y-2.60 Insider Trans-45.93% Shs Float69.09M Perf Month-16.71%
Income-190.20M PEG- EPS next Q-0.69 Inst Own75.60% Short Float8.89% Perf Quarter-21.24%
Sales21.10M P/S60.92 EPS this Y-43.30% Inst Trans0.17% Short Ratio9.22 Perf Half Y44.31%
Book/sh3.39 P/B4.82 EPS next Y10.30% ROA-34.40% Target Price32.13 Perf Year-40.42%
Cash/sh5.26 P/C3.11 EPS next 5Y- ROE-57.40% 52W Range9.12 - 34.89 Perf YTD8.06%
Dividend- P/FCF- EPS past 5Y- ROI-73.00% 52W High-53.14% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low79.28% ATR1.23
Employees171 Current Ratio6.20 Sales Q/Q-18.30% Oper. Margin- RSI (14)41.17 Volatility8.43% 6.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-47.00% Profit Margin- Rel Volume1.20 Prev Close16.97
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume665.99K Price16.35
Recom1.60 SMA20-9.83% SMA50-10.41% SMA2006.89% Volume799,636 Change-3.65%
Jan-15-21Resumed BofA Securities Buy $35
Jun-24-20Initiated H.C. Wainwright Buy $41
Apr-28-20Initiated Goldman Buy $32
Mar-06-20Initiated Citigroup Buy $40
Feb-27-20Initiated Barclays Overweight $36
Feb-19-20Initiated Stifel Buy $44
Nov-21-19Initiated BTIG Research Buy $28
Mar-04-19Initiated SVB Leerink Outperform
Mar-04-19Initiated Morgan Stanley Overweight $27
Mar-04-19Initiated BofA/Merrill Buy $26
Mar-04-19Initiated Barclays Overweight $27
May-06-21 04:05PM  
May-05-21 08:05PM  
04:05PM  
03:00PM  
01:32AM  
Mar-30-21 01:23PM  
Mar-25-21 04:05PM  
Mar-23-21 01:53PM  
Mar-04-21 04:05PM  
Feb-28-21 01:36AM  
Feb-25-21 04:05PM  
Jan-25-21 08:30AM  
Jan-20-21 04:15PM  
Jan-07-21 04:05PM  
Dec-29-20 11:42PM  
Dec-11-20 08:56AM  
Nov-12-20 11:18AM  
Nov-11-20 04:05PM  
Nov-10-20 06:45PM  
04:05PM  
Nov-09-20 05:30AM  
Nov-03-20 12:30PM  
Nov-02-20 07:44AM  
Oct-22-20 04:05PM  
Oct-06-20 08:54AM  
Sep-24-20 11:46AM  
Sep-16-20 03:23PM  
Sep-13-20 08:53AM  
Sep-03-20 04:05PM  
Aug-11-20 05:55PM  
04:05PM  
Aug-04-20 08:30AM  
Aug-03-20 12:31PM  
Jul-29-20 01:00PM  
07:32AM  
Jul-28-20 06:00PM  
Jul-24-20 06:12PM  
08:30AM  
Jul-21-20 05:00PM  
05:00PM  
Jul-15-20 07:31AM  
Jun-28-20 07:16PM  
Jun-25-20 09:00AM  
Jun-12-20 07:00PM  
Jun-03-20 04:01PM  
May-16-20 08:05AM  
May-13-20 09:25AM  
08:00AM  
May-07-20 08:30AM  
May-04-20 08:20AM  
May-03-20 07:00AM  
Apr-02-20 11:30AM  
Mar-31-20 10:34AM  
Mar-26-20 06:11AM  
Mar-25-20 05:00PM  
Mar-24-20 05:25PM  
04:05PM  
Mar-23-20 08:30AM  
Mar-17-20 12:30PM  
12:00PM  
11:30AM  
Mar-11-20 09:53AM  
Mar-06-20 07:25PM  
Feb-28-20 08:51AM  
Feb-24-20 08:30AM  
Feb-06-20 07:47AM  
Feb-05-20 08:00AM  
07:21AM  
Feb-03-20 06:00PM  
Jan-31-20 09:09AM  
08:00AM  
Jan-29-20 09:42PM  
Jan-28-20 08:30AM  
Jan-27-20 04:05PM  
Jan-17-20 08:45PM  
Jan-08-20 08:30AM  
Jan-06-20 08:30AM  
Dec-27-19 02:57PM  
Dec-20-19 08:30AM  
Dec-13-19 06:30AM  
06:28AM  
Dec-12-19 07:08PM  
Dec-11-19 04:05PM  
Dec-06-19 04:30PM  
07:39AM  
Dec-05-19 04:22PM  
Dec-04-19 09:15AM  
Nov-14-19 08:30AM  
Nov-12-19 04:05PM  
Nov-11-19 09:28AM  
Oct-28-19 07:46PM  
Sep-23-19 01:22PM  
Sep-20-19 10:02AM  
Sep-19-19 06:56AM  
Sep-09-19 08:00AM  
Sep-03-19 04:10PM  
Aug-12-19 04:10PM  
09:00AM  
Jul-18-19 10:26AM  
Jul-17-19 04:05PM  
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paul RobertChief Medical OfficerApr 07Option Exercise9.6022,300214,186236,019Apr 08 08:18 PM
Paul RobertChief Medical OfficerApr 07Sale19.2022,300428,050213,719Apr 08 08:18 PM
Paul RobertChief Medical OfficerMar 23Option Exercise8.1613,800112,608227,519Mar 24 04:36 PM
Paul RobertChief Medical OfficerMar 23Sale22.2113,800306,498213,719Mar 24 04:36 PM
Paul RobertChief Medical OfficerMar 22Option Exercise8.1630,000244,800243,719Mar 24 04:36 PM
Paul RobertChief Medical OfficerMar 22Sale22.9830,000689,376213,719Mar 24 04:36 PM
Paul RobertChief Medical OfficerMar 09Option Exercise8.3819,175160,592232,894Mar 10 06:29 PM
Paul RobertChief Medical OfficerMar 09Sale18.1219,175347,405213,719Mar 10 06:29 PM
Paul RobertChief Medical OfficerFeb 09Option Exercise8.3819,175160,594232,894Feb 11 05:08 PM
Paul RobertChief Medical OfficerFeb 09Sale20.8119,175399,055213,719Feb 11 05:08 PM
Paul RobertChief Medical OfficerJan 26Option Exercise8.4627,308231,082241,027Jan 27 06:53 PM
Paul RobertChief Medical OfficerJan 26Sale18.0027,308491,544213,719Jan 27 06:53 PM
Paul RobertChief Medical OfficerJan 25Option Exercise8.3030,000248,926243,719Jan 27 06:53 PM
Paul RobertChief Medical OfficerJan 25Sale18.0130,000540,225213,719Jan 27 06:53 PM
Paul RobertChief Medical OfficerJan 20Option Exercise8.648,56774,031222,286Jan 21 06:46 PM
Paul RobertChief Medical OfficerJan 20Sale18.008,567154,211213,719Jan 21 06:46 PM
Paul RobertChief Medical OfficerJan 19Option Exercise8.3030,000248,924243,719Jan 21 06:46 PM
Paul RobertChief Medical OfficerJan 19Sale18.1230,000543,552213,719Jan 21 06:46 PM
Paul RobertChief Medical OfficerJul 15Sale22.9610,000229,642213,719Jul 17 04:43 PM
MCGUIRE TERRANCEDirectorJun 23Sale31.544,377138,06312,853,817Jun 25 05:53 PM
Polaris Venture Management Co.10% OwnerJun 23Sale31.544,377138,06312,853,817Jun 25 05:47 PM
Paul RobertChief Medical OfficerJun 15Sale29.6110,000296,137223,719Jun 17 04:21 PM
Yu CalvinVice President, FinanceJun 03Sale31.261,34341,981110,686Jun 05 04:40 PM
King RobertChief Development OfficerMay 15Sale27.0015,000404,958477,317May 19 05:23 PM
Paul RobertChief Medical OfficerMay 15Sale27.0010,000270,026233,719May 19 05:23 PM